Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)
376.89
+7.05 (1.91%)
NASDAQ · Last Trade: Aug 18th, 2:48 PM EDT
Detailed Quote
Previous Close
369.84
Open
354.56
Bid
376.14
Ask
377.00
Day's Range
351.31 - 376.89
52 Week Range
200.63 - 377.46
Volume
469,724
Market Cap
6.45B
PE Ratio (TTM)
-29.61
EPS (TTM)
-12.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
420,903
Chart
About Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)
Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for liver and metabolic diseases, with an emphasis on addressing non-alcoholic steatohepatitis (NASH) and related conditions. The company’s research and development efforts center around its proprietary drug candidates that target and modulate key metabolic pathways, aiming to improve patient outcomes and provide effective treatment options. By leveraging cutting-edge science and clinical expertise, Madrigal is dedicated to advancing its pipeline of transformative therapies to meet the growing needs of patients suffering from complex liver diseases. Read More
Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment, Rezdiffra.
